Quicktome Software Suite
Omniscient Neurotechnology Pty, Ltd. · Decision date Sep 10, 2026
What did the FDA decide?
The FDA recorded a substantial equivalence decision dated September 10, 2026 for K261795, the Quicktome Software Suite submitted by Omniscient Neurotechnology Pty, Ltd. under product code QIH (regulation 21 CFR 892.2050, Class II). The submission was dated August 6, 2026 and received August 7, 2026. The primary predicate listed is K241083, the SIS System, also under QIH. Substantial equivalence is a clearance finding, not approval of a premarket approval application.
The described device is software-only and cloud-deployed, covering DICOM viewing, image fusion, 3D visualization, diffusion-weighted tract mapping, resting-state fMRI correlation maps, and atlas-assisted segmentation. The submission module adds CT-to-MRI co-registration, automatic extraction of implanted deep brain stimulation lead geometry from CT, and display of the lead model with registered deep-brain structures as an adjunctive visualization aid. Some processing steps use locked machine-learning components described in an AI/ML Model Card. The source does not state performance testing results, clinical outcome data, or the model card contents.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 10, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261795
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Omniscient Neurotechnology Pty, Ltd.
- Product code
- QIH
- Decision code
- SESE
- Decision date
- Sep 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated Radiological Image Processing Software.
- Applicant
- Omniscient Neurotechnology Pty, Ltd.
- Product code
- QIH
- FDA device class
- 2
FDA decision timeline
K261795 received
Application receipt date recorded by FDA.
K261795 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Clever OneK260372 | Ewoosoft Co., Ltd. | 510(k) clearance | Nov 4, 2026 | FDA |
PeekMed webK262667 | Peek Health, S.A. | 510(k) clearance | Nov 4, 2026 | FDA |
CINA-Aneurysm+K262147 | AVICENNA.AI | 510(k) clearance | Oct 19, 2026 | FDA |
Ligence HeartK261733 | UAB Ligence | 510(k) clearance | Oct 7, 2026 | FDA |
NeuroDRK262134 | Deep Reasoning Ai, Inc. | 510(k) clearance | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Omniscient Neurotechnology Pty, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Haymarket
Sources and methodology
- Original FDA record: K261795
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


